Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GamTBvac Vaccine for the Prevention of Pulmonary Tuberculosis
NCT04975737Phase 3Active, not recruiting
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of GamTBvac in Tuberculosis (TB). Started Jan 2022; status: active, not recruiting.
02
Drugs
GamTBvac
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04975737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975737.